Age-related macular degeneration: pathophysiology, management, and future perspectives

R Flores, Â Carneiro, M Vieira, S Tenreiro… - Ophthalmologica, 2021 - karger.com
Among older adults, age-related macular degeneration (AMD) is a prevalent disabling
condition that begins as subtle visual disturbances and can progress to permanent loss of …

[HTML][HTML] Global burden of dry age-related macular degeneration: a targeted literature review

NM Schultz, S Bhardwaj, C Barclay, L Gaspar… - Clinical …, 2021 - Elsevier
Purpose Age-related macular degeneration (AMD) is a leading cause of blindness,
particularly in higher-income countries. Although dry AMD accounts for 85% to 90% of AMD …

Prevalence of age-related macular degeneration in the US in 2019

DB Rein, JS Wittenborn, Z Burke-Conte… - JAMA …, 2022 - jamanetwork.com
Importance Age-related macular degeneration (AMD) is a leading cause of vision loss and
blindness. AMD prevalence has not been estimated for the US in over a decade and early …

Fives: A fundus image dataset for artificial Intelligence based vessel segmentation

K Jin, X Huang, J Zhou, Y Li, Y Yan, Y Sun, Q Zhang… - Scientific data, 2022 - nature.com
Retinal vasculature provides an opportunity for direct observation of vessel morphology,
which is linked to multiple clinical conditions. However, objective and quantitative …

Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map

AM Khanani, MA Zarbin, MR Barakat… - JAMA …, 2022 - jamanetwork.com
Importance Limited data exist on the real-world safety outcomes of patients with neovascular
age-related macular degeneration treated with brolucizumab (Beovu). Objective To …

A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration

H Heloterä, K Kaarniranta - Cells, 2022 - mdpi.com
Age-related macular degeneration (AMD) is the leading cause of visual impairment in the
aging population with a limited understanding of its pathogenesis and the number of …

Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial

CC Wykoff, DM Brown, K Reed, AJ Berliner… - JAMA …, 2023 - jamanetwork.com
Importance Aflibercept, 8 mg, may have greater therapeutic benefits compared with
aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD) …

A multimodal deep learning system to distinguish late stages of AMD and to compare expert vs. AI ocular biomarkers

KA Thakoor, J Yao, D Bordbar, O Moussa, W Lin… - Scientific reports, 2022 - nature.com
Abstract Within the next 1.5 decades, 1 in 7 US adults is anticipated to suffer from age-
related macular degeneration (AMD), a degenerative retinal disease which leads to …

Retinal specialist versus artificial intelligence detection of retinal fluid from OCT: age-related eye disease study 2: 10-year follow-on study

TDL Keenan, TE Clemons, A Domalpally, MJ Elman… - Ophthalmology, 2021 - Elsevier
Purpose To evaluate the performance of retinal specialists in detecting retinal fluid presence
in spectral domain OCT (SD-OCT) scans from eyes with age-related macular degeneration …

Mechanisms of macular edema

CD Haydinger, LB Ferreira, KA Williams… - Frontiers in …, 2023 - frontiersin.org
Macular edema is the pathological accumulation of fluid in the central retina. It is a
complication of many retinal diseases, including diabetic retinopathy, retinal vascular …